BACKGROUND AND PURPOSE:7T MR imaging has led to improved detection and classification of cortical MS lesions, mainly based on T2*-weighted gradient-echo sequences. Depiction of cortical GM by using the recommended MS imaging protocol has not yet been investigated at 7T. We aimed to investigate prospectively which recommended sequence for clinical use has the highest value at 7T, in terms of GM and WM lesion detection.
In multiple sclerosis (MS), a histopathological distinction is made between different stages of white matter (WM) lesions. These lesions are characterized as preactive, active, chronic active or chronic inactive, depending on the degree of microglia activation and degree of demyelination. The different lesions are not distinguishable on conventional magnetic resonance imaging (MRI) scans at standard clinical field strengths, but might be distinguished using more advanced, quantitative MRI methods, such as T1 relaxation time (T1-RT) mapping. To investigate this, postmortem brain material from 20 MS patients was investigated, using both T1-RT MRI at 1.5T and histopathology. The brain material contained a total of 9 preactive, 18 active, 30 chronic active and 14 chronic inactive lesions, as well as 38 areas of normal appearing WM (NAWM). Our results show that, at 1.5T, T1-RT qMRI can only distinguish between categories NAWM/preactive, active and chronic WM lesions. Advanced imaging at standard field strengths, such as conventional imaging measures, is therefore insufficient to differentiate the WM lesions in MS, and higher field strengths may be required to achieve better pathological differentiation of these lesions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.